Respiratory Disorders Treatment Market Size, Share, Growth Report 2030

The global Respiratory Disorders Treatment market accrued earnings worth approximately 98.9 (USD Billion) in 2020 and is predicted to gain revenue of about 112.5(USD Billion) by 2028, is set to record a CAGR of nearly 6.1% over the period from 2021 to 2028. The report offers assessment and analysis of the Respiratory Disorders Treatment market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Billion).

Report Scope :

Respiratory Disorders Treatment Market: Outlook

Respiratory disorders are life-threatening health problems and classified under four categories such as acute disorders, chronic ailments, occupational lung diseases, and parenchymal lung ailments. Acute disorders include influenza and pneumonia, chronic ailments are asthma and chronic obstructive pulmonary disease, and occupational lung diseases include asbestosis, byssinosis, & coal worker’s pneumoconiosis. Additionally, parenchymal lung ailments encompass immune related lung disorders. Furthermore, various kinds of therapies are utilized for treating these respiratory disorders that include mind-body therapies, integrative modalities, pharmacotreatment, supplements, nutrition, and self-care strategies.

Additionally, respiratory disorders are both non-communicable & communicable that can prove to be fatal for patients and result in mortality, economic burden on patients, and disability adjusted life years. Asthma is one of the best examples of non-communicable respiratory ailment and tuberculosis is one of the most common communicable respiratory diseases. Today, most of chronic obstructive pulmonary disorders are treated through inhaled corticosteroids. Apart from this, chronic respiratory disorders can be treated with bronchodilator and antibiotics. Moreover, COVID-19 is being treated through Remdesivir inoculation, ingestion of Paracetamol, and plasma therapies.

Respiratory Disorders Treatment Market: Growth Drivers

Massive use of leukotriene blocking agents in treating asthma due to its proven efficacy and launching of new drugs for treating respiratory disorders will benefit growth of respiratory disorders treatment market. Apparently, rise in cases of lung transplantation in countries such as the U.S. and the UK is likely to aid respiratory disorders treatment industry expansion. Lung tissue repair & regeneration helps in rebuilding lungs after suffering damages from respiratory disorders. Large-scale use of mepolizumab and omalizumab for treating severe asthma to drive business landscape. This will further add towards growth of respiratory disorders treatment market over forthcoming years. Breakthroughs in drug development for treating respiratory disorders will embellish growth of respiratory disorders treatment industry during forecast period.

Furthermore, large-scale use of translational lung medicine for treating respiratory ailments will proliferate expansion of respiratory disorders treatment market. Rise in research on lung microbiome will help in new drug discovery for treating chronic respiratory illness, thereby providing lucrative growth avenues for respiratory disorders treatment industry. Increase in respiratory illness due to rise in pollution due to emissions from vehicles on roads along with rise in combined drug therapy for treating respiratory disorders will multiply development of respiratory disorders treatment industry.

Regional Landscape

North America To Contribute Substantially Towards Market Profitability By 2028

The regional market growth during forecast timeline can be attributed to cost-efficiency of interventions for chronic obstructive pulmonary disorders & asthma in countries such as the U.S. and Canada. In addition to this, chronic respiratory disorders are a huge burden for healthcare systems in the U.S. and this will enhance market penetration in the subcontinent. Additionally, early risk diagnosis, preventive measures, participation of individuals & communities, and preemptive approaches will boost business growth trends. Development of advanced tools including RNA interference, cell-based approaches, tissue engineering, database sharing, high-throughput proteomics technologies, synthetic biology, imaging, microfluidics, and nanotechnology will steer regional market size.

Request Free Sample

Competitive Landscape

Key participants profiled in study and impacting industry growth are Mylan N.V., GlaxoSmithKline plc, Novartis AG, Cipla, Roche Diagnostics, AstraZeneca plc, Sanofi, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries, CHIESI Farmaceutici S.p.A, and Vertex Pharmaceuticals Incorporated.  

The global Respiratory Disorders Treatment Market is segmented as follows:

By Disease

• Asthma
• Chronic Obstructive Pulmonary Disease [COPD]
• Lung Cancer
• Respiratory Tract Infection
• Allergic Rhinitis
• Cystic Fibrosis [CF]

By Drug Class

• Bronchodilators 
• Corticosteroids
• Combination Drugs
• Antibiotics
• Target Therapy
• Immunotherapy
• CFTR

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Route of Administration

• Oral
• Nasal
• Injectable

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa